I honestly expect transparency and for those items of so open for interpretation that parameters be defined better. I would expect that if they were going to copy and paste and old 10k that they update it accurately and not leave outdated information in it. I would hope that the lack of attention to detail does not translated into our science. I mean I love the info about the multiple mylonoma. Wasn't expecting that. But to hear that tablet has been stopped when not 2 months ago they were stating it was market ready. Was that old info or new? My point is that when you leave a mess the interpretation is really open ended. Whats true... whats not? its really anyone's best guess. From such a professional appearing company that wants to up list I really expected more effort to be given. That's all.
I'm personally disappointed in the 10k. If I had been entrusted with over 100 million of peoples money and have such a stellar product line I would have made sure that what was released was updated and well articulated. Hope we have a 10Q and several awesome 8ks to clear some of this up.
(1)
(0)
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links